Does depression with current suicidal ideation lead to treatment-resistant depression? Two large naturalistic cohorts of outpatients with depression and current suicidal ideation

被引:2
|
作者
Nobile, Benedicte [1 ,2 ]
Gourguechon-Buot, Elia [1 ,2 ]
Olie, Emilie [1 ,2 ]
Malestroit, Manon [1 ,2 ]
Haffen, Emmanuel [4 ]
Gorwood, Philip [3 ]
Courtet, Philippe [2 ]
机构
[1] CHU, Dept Emergency Psychiat & Postacute Care, Montpellier, France
[2] Univ Montpellier, IGF, CNRS, INSERM, Montpellier, France
[3] Inst Psychiat & Neurosci Paris, Inserm, UMRS1266, Paris, France
[4] Univ Franche Comte, CHU Besancon, Serv Psychiat Adulte, Lab Neurosci,CIC 1431,INSERM,UBFC, Besancon, France
关键词
Depression; Treatment-resistant depression; Suicidal ideation; RISK-FACTORS; EARLY IMPROVEMENT; MAJOR DEPRESSION; HOSPITAL ANXIETY; DISORDER; ANTIDEPRESSANTS; SCALE; METAANALYSIS; IMPULSIVITY; ADOLESCENT;
D O I
10.1016/j.psychres.2024.116249
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
As treatment-resistant depression (TRD) is linked to suicidal behaviors and suicidal risk is a predictor of TRD, depression with current suicidal ideation (SI) may lead to TRD. Early identification of TRD risk factors in patients with depression and current SI is crucial. The aims of our study were: i) to identify risk factors for depression nonremission and TRD in patients with depression and current SI; ii) to assess if SI at baseline mediated the relationship between depression severity at baseline and depression remission at week 6. We analyzed data from two large, prospective, naturalistic French cohorts of adult outpatients with depression (DSM-IV criteria) followed for 6 weeks after starting or changing antidepressants (LUEUR and GENESE). Sociodemographic and clinical characteristics, along with early symptom improvement, were compared between patients with and without current SI using logistic regression models (univariate and multivariate). Patients with antidepressant change or initiation were analyzed separately. Those without depression remission at week 6 after an antidepressant change were considered TRD cases. In patients with antidepressant change, the major predictor of non-remission was poorer early improvement (at week 2) of anxiety. For patients with treatment initiation, SI at baseline mediated the relation between depression severity at baseline and depression remission. Depression severity at baseline alone did not explain depression remission. Clinicians should systematically target with specific pharmacological and non-pharmacological treatments anxiety and SI and assess their changes in the short term to increase the chance of depression remission in depressed patients with current SI.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Depression and Suicidal Ideation During Two Psychosocial Treatments in Older Adults with Major Depression and Dementia
    Kiosses, Dimitris N.
    Rosenberg, Paul B.
    McGovern, Amanda
    Fonzetti, Pasquale
    Zaydens, Hana
    Alexopoulos, George S.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 48 (02) : 453 - 462
  • [22] Treating suicidal ideation in the context of depression
    Renee A. Schneider
    Shih Yin Chen
    Anita Lungu
    Joseph R. Grasso
    BMC Psychiatry, 20
  • [23] Ketamine and suicidal ideation in depression: Jumping the gun?
    Rajkumar, R.
    Fam, J.
    Yeo, E. Y. M.
    Dawe, G. S.
    PHARMACOLOGICAL RESEARCH, 2015, 99 : 23 - 35
  • [24] Depression, Suicidal Ideation, and Suicidal Attempt Presenting to the Emergency Department: Differences Between These Cohorts
    Chakravarthy, Bharath
    Hoonpongsimanont, Wirachin
    Anderson, Craig L.
    Habicht, Michael
    Bruckner, Tim
    Lotfipour, Shahram
    WESTERN JOURNAL OF EMERGENCY MEDICINE, 2014, 15 (02) : 211 - 216
  • [25] Suicidal ideation, anxiety, and depression in patients with multiple sclerosis
    Tauil, Carlos Bernardo
    Grippe, Talyta Cortez
    Dias, Ronaldo Maciel
    Castello Dias-Carneiro, Rafael Paterno
    Carneiro, Narel Moita
    Rodrigues Aguilar, Ana Carolina
    da Silva, Flavia Martins
    Bezerra, Felipe
    de Almeida, Leonardo Kenzo
    Massarente, Vitoria Lana
    Giovannelli, Elaine de Carvalho
    Tilbery, Charles Peter
    Brandao, Carlos Otavio
    Santos, Leonilda Maria B.
    dos Santos-Neto, Leopoldo
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2018, 76 (05) : 296 - 301
  • [26] Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/ esketamine
    Singh, Balwinder
    Voort, Jennifer L. Vande
    Pazdernik, Vanessa K.
    Frye, Mark A.
    Kung, Simon
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 351 : 534 - 540
  • [27] Suicidal ideation and physical illness: Does the link lie with depression?
    Sanna, Livia
    Stuart, Amanda L.
    Pasco, Julie A.
    Kotowicz, Mark A.
    Berk, Michael
    Girardi, Paolo
    Williams, Lana J.
    JOURNAL OF AFFECTIVE DISORDERS, 2014, 152 : 422 - 426
  • [28] Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
    Ionescu, Dawn F.
    Bentley, Kate H.
    Eikermann, Matthias
    Taylor, Norman
    Johnson-Akeju, Oluwaseun
    Swee, Michaela B.
    Pavone, Kara J.
    Petrie, Samuel R.
    Dording, Christina
    Mischoulon, David
    Alpert, Jonathan E.
    Brown, Emery N.
    Baer, Lee
    Nock, Matthew K.
    Fava, Maurizio
    Cusin, Cristina
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 243 : 516 - 524
  • [29] Factors associated with transitioning from suicidal ideation to suicide attempt in the short-term: Two large cohorts of depressed outpatients
    Porras-Segovia, Alejandro
    Nobile, Benedicte
    Olie, Emilie
    Gourguechon-Buot, Elia
    Garcia, Enrique Baca
    Gorwood, Philip
    Abascal-Peiro, Sofia
    Courtet, Philippe
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 335 : 155 - 165
  • [30] Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-On Trial Treatment for Acute Bipolar Depression Patients With Suicidal Ideation
    Wang, Dandan
    Guo, Xiaonan
    Huang, Qi
    Wang, Zhong
    Chen, Jingkai
    Hu, Shaohua
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (10)